real-time news and commentary for investors
Wednesday, Jan 2
Questcor Pharmaceuticals (QCOR) acquires Canadian biotech firm BioVectra for C$50M. BioVectra is...
Questcor Pharmaceuticals (QCOR) acquires Canadian biotech firm BioVectra for C$50M. BioVectra is a contract manufacturing services provider to the global pharmaceutical and biotechnology industry and manufactures active pharmaceutical ingredients, chemical intermediates, and bioprocessing reagents. The acquisition is part of a larger strategy by QCOR to lock down a key ingredient maker for its only drug, Acthar, which isn't patent-protected, and will help to protect the drug's manufacturing process trade secrets.